Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Renewed Emphasis on Therapeutic Angiogenesis Research for CAD.

Biotechnology healthcare·2012
See all related articles

Related Experiment Video

Updated: Jul 9, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Combating cardiovascular disease with angiogenic therapy.

Jack Jacobs1

  • 1CardioVascular BioTherapeutics, Inc., 1635 Village Center Circle, Las Vegas, NV 89134, USA. jjacobs@cvbt.com

Drug Discovery Today
|December 7, 2007
PubMed
Summary

Therapeutic angiogenesis aims to grow new blood vessels for cardiovascular disease patients. Recent trials suggest protein-based therapy shows promise for advanced atherosclerotic disease, offering a viable treatment option.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Experiment Videos

Last Updated: Jul 9, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Area of Science:

  • Cardiovascular medicine
  • Regenerative medicine
  • Vascular biology

Background:

  • Cardiovascular disease is a leading cause of death globally.
  • Therapeutic angiogenesis has long promised clinical benefits for patients with poor blood perfusion.
  • Previous animal studies showed success, but human trials yielded limited efficacy data.

Purpose of the Study:

  • To evaluate the potential of therapeutic angiogenesis as a treatment for cardiovascular disease.
  • To assess the efficacy of protein-based angiogenesis therapy in human clinical trials.
  • To identify viable treatment options for patients with advanced atherosclerotic disease.

Main Methods:

  • Review of clinical studies on therapeutic angiogenesis.
  • Analysis of emerging results from recent protein-based angiogenesis trials.
  • Focus on patients with advanced atherosclerotic disease and poor blood perfusion.

Main Results:

  • Early angiogenesis therapies (protein, gene, cell-based) showed limited success in human trials.
  • Recent clinical trials indicate protein-based angiogenesis therapy is a potential viable option.
  • Emerging data suggests efficacy in patients with advanced atherosclerotic disease.

Conclusions:

  • Protein-based angiogenesis therapy shows emerging promise for cardiovascular disease.
  • Knowledge from past clinical study shortcomings has informed newer trial designs.
  • This approach may offer a viable treatment for advanced atherosclerotic disease patients.